Predictive Significance of Combined Plasmatic Detection of <scp>BRAF</scp> Mutations and <scp>S100B</scp> Tumor Marker in Early‐Stage Malignant Melanoma
There is still no general consensus on molecular markers for deciding the appropriateness of adjuvant treatment of early-stage melanoma. We have shown for the first time that the combined determination of the ctDNA BRAF<sup>mut</sup> oncogene (liquid biopsy) and the high level of tumor marker S100B in pre- and postoperative plasma samples can identify patients with the worst prognosis and the highest risk of tumor recurrence. Therefore, modern adjuvant therapy would be appropriate for these patients with resectable melanoma, regardless of disease stage.
Authors
- Ondřej Topolčan (ORCID: https://orcid.org/0000-0001-6622-390X)
- Filip Janku
- Jindra Windrichová (ORCID: https://orcid.org/0000-0003-0365-0968)
- Radek Kučera (ORCID: https://orcid.org/0000-0002-2739-2302)
- Jan Říčař
- Inka Třešková (ORCID: https://orcid.org/0000-0003-1440-0120)
- Kristýna Pivovarčíková (ORCID: https://orcid.org/0000-0002-9553-0105)
- Kateřina Houfková
- Tomas Fikrle
- Jiří Polívka
- Helen J. Huang (ORCID: https://orcid.org/0000-0002-6308-346X)
- Martin Pešta (ORCID: https://orcid.org/0000-0001-8187-0566)
- Mohamed A. Gouda (ORCID: https://orcid.org/0000-0003-4829-6739)
- Vlastimil Woznica
- Mahyar Sharif Bagheri (ORCID: https://orcid.org/0000-0002-1228-1300)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Charles University (CZ)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/cam4.70313
- Citations
- 5
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Univerzita Karlova v Praze
- Ministerstvo Zdravotnictví Ceské Republiky
- National Institutes of Health
- University of Texas MD Anderson Cancer Center